2026-08-05T13:43:57Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/114362024-09-27T22:19:08Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Muzzi, Alessandro author Brozzi, Alessandro author Serino, Laura author Bodini, Margherita author Abad, Raquel author Caugant, Dominique author Comanducci, Maurizio author Lemos, Ana Paula author Gorla, Maria Cecilia author Křížová, Pavla author Mikula, Claudia author Mulhall, Robert author Nissen, Michael author Nohynek, Hanna author Simões, Maria João author Skoczyńska, Anna author Stefanelli, Paola author Taha, Muhamed-Kheir author Toropainen, Maija author Tzanakaki, Georgina author Vadivelu-Pechai, Kumaran author Watson, Philip author Vazquez-Moreno, Julio Alberto author Rajam, Gowrisankar author Rappuoli, Rino author Borrow, Ray author Medini, Duccio author 2019 The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting strain coverage by the 4CMenB vaccine. From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. Overall, 81% of the strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS predicted strain coverage in other countries was 58-88%. gMATS can replace MATS in predicting 4CMenB strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates. Vaccine. 2019 Feb 8;37(7):991-1000. 10.1016/j.vaccine.2018.12.061 1873-2518 0264-410X Vaccine 30661831 http://hdl.handle.net/20.500.12105/11436 Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide